Genzyme-backed program to chronicle lives of patients with MS

Genzyme-backed program to chronicle lives of patients with MS
Genzyme-backed program to chronicle lives of patients with MS
The lives of five patients with mutiple sclerosis will be chronicled online as part of a new program jointly developed by the National MS Society and Sanofi's Genzyme unit. The program, called Everyday Matters, chose the patients from a pool of 1,200 entries to receive individual support as they share experiences.

Organizers say they will seek to engage and inspire those living with or affected by MS by tapping into the field of positive psychology, drawing on the achievements of the patients to help inspire others. Patients will be tracked through a combination of personal text, video, and photo journals, all to be showcased on the website

The patients -- who include a school teacher and single mom -- will focus on the top five aspects of life, as identified by MS patients in a June 2012 poll by the society: wellness, work/education, relationships, family and empowerment. Emmy-winning producer Kristen Adams, herself an individual living with MS, will help film the stories. A life coach who also has MS, Michelle Clos, will provide one-on-one coaching, and best-selling author of The Happiness Advantage, Shawn Achor, will guide efforts.

The site will also offer general resources, including toolkits that address the five core concerns highlighted in the MS society's survey.

“I know first-hand that ‘staying positive' can become that much more challenging after being diagnosed with a chronic and unpredictable disease like MS,” Clos said in a statement.

In June Genzyme submitted Lemtrada (alemtuzumab), for relapsing MS treatment, to the FDA and European regulators. An annual injection, the drug would compete against MS treatments like Novartis' Gilenya (fingolimod), Teva's Copaxone (glatiramer) and Biogen-Idec's Tysabri (natalizumab).

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions